Immunic
IMUX
20 hedge funds and large institutions have $20.7M invested in Immunic in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 6 closing their positions.
38% more capital invested
Capital invested by funds: $15M → $20.7M (+$5.75M)
0.63% more ownership
Funds ownership: 1.49% → 2.11% (+0.63%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
17% less funds holding
Funds holding: 24 → 20 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$5.24M |
| 2 |
Renaissance Technologies
New York
|
+$155K |
| 3 |
BlackRock
New York
|
+$73.3K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$50.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$105K |
| 2 |
Credit Agricole
Montrouge Cedex,
France
|
-$97K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$17K |
| 4 |
JP Morgan Chase
New York
|
-$10.6K |
| 5 |
QT
Quantamental Technologies
White Plains,
New York
|
-$10K |
IMUX Hedge Fund Activity: Q4 2019 in Review
20 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q4 2019, worth a combined $20.7M — up 38% from $15M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IMUX and 2 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Artal Group, opening a new position worth an estimated $5.24M. The largest seller was Geode Capital Management, exiting entirely with an estimated $105K sold.
- 20 institutional investors held Immunic (IMUX) as of Q4 2019, down from 24 in Q3 2019.
- Funds reported $20.7M of Immunic stock for Q4 2019, up 38% quarter-over-quarter.
- 2 funds opened new Immunic positions in Q4 2019 and 6 closed out, a net change of -4 holders.
- The largest Immunic buyer in Q4 2019 was Artal Group, an estimated $5.24M added.
- The largest Immunic seller in Q4 2019 was Geode Capital Management, an estimated $105K sold.
Based on aggregated 13F filings for Q4 2019.